Published in Autoimmunity reviews
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, antibiotics and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent ...
Published in Autoimmunity reviews
Published in Autoimmunity reviews
Published in Autoimmunity reviews
Published in Autoimmunity Reviews
Published in Autoimmunity Reviews
• COVID-19 infection share clinical/laboratory features with “hyperferritinemic syndromes”. • A cytokine storm is responsible for COVID-19 systemic inflammatory response. • COVID-19 severe infection benefit from b-DMARDs targeting specific cytokines.
Published in Autoimmunity reviews
This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population. In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referr...
Published in Autoimmunity reviews
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. This is a retrospective study ...
Published in Autoimmunity reviews
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent ...
Published in Autoimmunity reviews
